A complete response to dabrafenib and trametinib treatment in patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations leads to greater survival outcomes at 5 years, according to an analysis of data from the COMBI-d* and COMBI-v** trials.
Adjuvant treatment with ipilimumab significantly improved overall survival (OS) among patients with resected high-risk melanoma compared with high-dose interferon-α2b (HDI*), according to final results of the North American Intergroup E1609** trial presented at ASCO 2019.
Neoadjuvant treatment with trastuzumab emtansine (T-DM1) plus pertuzumab led to an elevated risk of 3-year event-free survival (EFS) events in patients with HER2-positive breast cancer, according to a secondary analysis of the KRISTINE* trial presented at ASCO 2019.
Patients with previously untreated metastatic nonsquamous non-small-cell lung cancer (NSCLC) may have their overall survival (OS) and progression-free survival (PFS) approximately doubled with pembrolizumab in combination with platinum-based chemotherapy vs chemotherapy alone, according to updated results of the KEYNOTE-189 trial reported at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting.
Podcast: Dr Sara Hurvitz highlights that
the addition of ribociclib to endocrine therapy improved overall survival in
premenopausal women with HR+, HER2- advanced breast cancer, according to the
The addition of the CDK* 4/6 inhibitor ribociclib to endocrine therapy significantly extended overall survival (OS) in premenopausal women with HR+ HER2- advanced breast cancer, as evidenced in the phase III MONALEESA-7** trial.
Adding apalutamide to androgen-deprivation therapy (ADT) significantly extends radiographic progression-free survival (rPFS) and overall survival (OS) in patients with metastatic castration-sensitive prostate cancer (mCSPC) compared with ADT alone, the TITAN* study shows.
The taxane-based TPEx regimen demonstrated encouraging overall survival (OS) benefit for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) compared with the fluorouracil (5FU)-based EXTREME regimen, according to the results of the TPExtreme* trial presented at ASCO 2019.
Pembrolizumab is noninferior to standard chemotherapy for overall survival (OS) in advanced gastric or gastroesophageal junction (G/GEJ) cancer in the first-line setting, thus providing a potential alternative treatment option for patients with G/GEJ, according to the KEYNOTE-062 study presented at ASCO 2019.
Results of the registrational phase I/II ARROW trial of pralsetinib, presented at the European Society for Medical Oncology (ESMO) Virtual Congress 2020, reveal overall response rates (ORRs) of ≥60 percent in pretreated and treatment-naïveRET-mutated (RETmut) medullary thyroid cancer (MTC) patients.